These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22193214)

  • 21. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
    Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
    Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to advise aspirin use in patients who need NSAIDs.
    Sopena F; Lanas A
    Curr Pharm Des; 2007; 13(22):2248-60. PubMed ID: 17691998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
    Stillman MJ; Stillman MT
    Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
    Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
    Blain H; Jouzeau JY; Netter P; Jeandel C
    Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
    Antman EM; Bennett JS; Daugherty A; Furberg C; Roberts H; Taubert KA;
    Circulation; 2007 Mar; 115(12):1634-42. PubMed ID: 17325246
    [No Abstract]   [Full Text] [Related]  

  • 38. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.
    Bakhriansyah M; Souverein PC; de Boer A; Klungel OH
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1141-1148. PubMed ID: 28370857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.